No, bisoprolol and propranolol should not be given together
Two different beta-blockers from the same class should not be administered together. This is explicitly contraindicated by major clinical practice guidelines.
Guideline-Based Recommendation
The 2017 ACC/AHA Hypertension Guidelines provide clear, unequivocal guidance on this issue: "Drug combinations that have similar mechanisms of action or clinical effects should be avoided. For example, 2 drugs from the same class should not be administered together (e.g., 2 different beta blockers, ACE inhibitors, or nondihydropyridine CCBs)" 1.
This recommendation is consistently repeated across multiple versions of the same guideline published in different journals 2, 3, 4, emphasizing its importance as a fundamental principle of antihypertensive therapy.
Clinical Rationale
Why This Combination Is Problematic:
Additive adverse effects without additional benefit: Both bisoprolol (a cardioselective beta-1 blocker) and propranolol (a non-selective beta blocker) work through the same mechanism—blocking beta-adrenergic receptors. Combining them provides no complementary mechanism of action 1.
Increased risk of serious adverse events: The FDA drug label for propranolol specifically warns about additive effects when beta-blockers are combined, noting risks of excessive bradycardia, hypotension, heart block, and heart failure 5.
Excessive beta-blockade: Using two beta-blockers simultaneously can lead to:
- Severe bradycardia (dangerously slow heart rate)
- Profound hypotension
- Worsening heart failure
- Complete heart block
- Cardiogenic shock
What To Do Instead
If beta-blockade is insufficient with one agent:
Optimize the dose of the single beta-blocker before considering alternatives
Add a complementary drug class such as:
- ACE inhibitor or ARB (targets renin-angiotensin system)
- Dihydropyridine calcium channel blocker (e.g., amlodipine)
- Thiazide or thiazide-like diuretic
Switch to a different beta-blocker if the current one is ineffective or poorly tolerated, rather than adding a second one
Common Clinical Pitfall
A provider might mistakenly think combining a cardioselective beta-blocker (bisoprolol) with a non-selective one (propranolol) provides "broader coverage" of beta receptors. This is incorrect—it simply increases toxicity risk without therapeutic benefit. The guideline prohibition applies to all combinations of beta-blockers, regardless of their selectivity profiles 1.
The only exception to avoiding same-class combinations mentioned in guidelines involves diuretics (where thiazide, potassium-sparing, and loop diuretics can be combined) and calcium channel blockers (where dihydropyridine and non-dihydropyridine types can be combined) 1. Beta-blockers are not included in these exceptions.